Heron Therapeutics, Inc. (HRTX): Price and Financial Metrics


Heron Therapeutics, Inc. (HRTX): $12.36

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HRTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 499

in industry

HRTX POWR Grades


  • HRTX scores best on the Value dimension, with a Value rank ahead of 64.3% of US stocks.
  • The strongest trend for HRTX is in Momentum, which has been heading down over the past 31 weeks.
  • HRTX's current lowest rank is in the Momentum metric (where it is better than 5.04% of US stocks).

HRTX Stock Summary

  • HRTX's went public 33.95 years ago, making it older than 91.46% of listed US stocks we're tracking.
  • For HRTX, its debt to operating expenses ratio is greater than that reported by just 11.58% of US equities we're observing.
  • As for revenue growth, note that HRTX's revenue has grown -40.43% over the past 12 months; that beats the revenue growth of merely 9.07% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Heron Therapeutics Inc are CYCN, PDFS, PXLW, CUE, and APTX.
  • Visit HRTX's SEC page to see the company's official filings. To visit the company's web site, go to www.herontx.com.

HRTX Valuation Summary

  • HRTX's price/earnings ratio is -5.7; this is 116.76% lower than that of the median Healthcare stock.
  • Over the past 243 months, HRTX's price/sales ratio has gone up 2.8.
  • HRTX's price/sales ratio has moved up 2.8 over the prior 243 months.

Below are key valuation metrics over time for HRTX.

Stock Date P/S P/B P/E EV/EBIT
HRTX 2020-10-01 10.8 4.2 -6.9 -6.4
HRTX 2018-04-26 64.8 15.2 -10.1 -9.7
HRTX 2017-07-25 187.0 9.0 -4.8 -4.8
HRTX 2008-03-07 151.2 1.1 -2.3 -0.2
HRTX 2003-04-16 3.7 1.4 -5.7 -4.2
HRTX 2001-12-17 14.1 2.6 -22.3 -14.0

HRTX Growth Metrics

  • Its 4 year price growth rate is now at -19.35%.
  • Its 4 year cash and equivalents growth rate is now at 51.85%.
  • Its year over year price growth rate is now at 16.68%.
Over the past 49 months, HRTX's revenue has gone up $78,345,000.

The table below shows HRTX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 83.256 -193.823 -228.313
2020-12-31 88.638 -184.82 -227.278
2020-09-30 103.116 -159.243 -222.917
2020-06-30 125.775 -142.66 -198.284
2020-03-31 139.766 -108.491 -193.316
2019-12-31 145.968 -124.58 -204.749

HRTX Price Target

For more insight on analysts targets of HRTX, see our HRTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $32.89 Average Broker Recommendation 1.31 (Strong Buy)

HRTX Stock Price Chart Interactive Chart >

Price chart for HRTX

HRTX Price/Volume Stats

Current price $12.36 52-week high $22.40
Prev. close $12.36 52-week low $12.13
Day low $12.19 Volume 776,000
Day high $12.50 Avg. volume 1,356,649
50-day MA $14.11 Dividend yield N/A
200-day MA $16.70 Market Cap 1.26B

Heron Therapeutics, Inc. (HRTX) Company Bio


Heron Therapeutics is a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs. The company was founded in 1983 and is based in Redwood City, CA.


HRTX Latest News Stream


Event/Time News Detail
Loading, please wait...

HRTX Latest Social Stream


Loading social stream, please wait...

View Full HRTX Social Stream

Latest HRTX News From Around the Web

Below are the latest news stories about Heron Therapeutics Inc that investors may wish to consider to help them evaluate HRTX as an investment opportunity.

Heron Therapeutics (NASDAQ:HRTX) Share Prices Have Dropped 66% In The Last Three Years

If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...

Yahoo | July 31, 2021

Heron Therapeutics Announces Publication of Results from HOPE (Helping Opioid Prescription Elimination), Showing ZYNRELEF™ Minimizes the Need for Opioids in a Real-World Setting, With 95% of Patients Experiencing an Opioid-free Recovery

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the results from the HOPE Hernia-1 study of ZYNRELEF (bupivacaine and meloxicam) in hernia repair surgery have been published online by Pain and Therapy in an article entitled, "Opioid-Free Recovery After Hernia Repair With HTX-011 as the Foundation of a Non-Op

Yahoo | July 28, 2021

Will Heron Therapeutics (HRTX) Report Negative Q2 Earnings? What You Should Know

Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 28, 2021

Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF™

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the online publication of new analysis evaluating the efficacy and safety of ZYNRELEF (bupivacaine and meloxicam) extended-release solution in adults aged 65 years and older undergoing bunionectomy and hernia repair from the Phase 3 EPOCH 1 and EPOCH 2 studies.

Yahoo | July 21, 2021

Heron Therapeutics Announces 340B Prime Vendor Contract with Apexus for ZYNRELEF

SAN DIEGO, July 6, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that it

PR Newswire | July 6, 2021

Read More 'HRTX' Stories Here

HRTX Price Returns

1-mo -16.88%
3-mo -27.76%
6-mo -37.67%
1-year -24.13%
3-year -66.23%
5-year -36.39%
YTD -41.60%
2020 -9.94%
2019 -9.41%
2018 43.31%
2017 38.17%
2016 -50.94%

Continue Researching HRTX

Here are a few links from around the web to help you further your research on Heron Therapeutics Inc's stock as an investment opportunity:

Heron Therapeutics Inc (HRTX) Stock Price | Nasdaq
Heron Therapeutics Inc (HRTX) Stock Quote, History and News - Yahoo Finance
Heron Therapeutics Inc (HRTX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7815 seconds.